282 related articles for article (PubMed ID: 16505118)
1. Rosiglitazone suppresses human lung carcinoma cell growth through PPARgamma-dependent and PPARgamma-independent signal pathways.
Han S; Roman J
Mol Cancer Ther; 2006 Feb; 5(2):430-7. PubMed ID: 16505118
[TBL] [Abstract][Full Text] [Related]
2. Fibronectin stimulates non-small cell lung carcinoma cell growth through activation of Akt/mammalian target of rapamycin/S6 kinase and inactivation of LKB1/AMP-activated protein kinase signal pathways.
Han S; Khuri FR; Roman J
Cancer Res; 2006 Jan; 66(1):315-23. PubMed ID: 16397245
[TBL] [Abstract][Full Text] [Related]
3. Peroxisome proliferator-activated receptor-gamma and retinoic acid X receptor alpha represses the TGFbeta1 gene via PTEN-mediated p70 ribosomal S6 kinase-1 inhibition: role for Zf9 dephosphorylation.
Lee SJ; Yang EK; Kim SG
Mol Pharmacol; 2006 Jul; 70(1):415-25. PubMed ID: 16611854
[TBL] [Abstract][Full Text] [Related]
4. Rosiglitazone inhibits alpha4 nicotinic acetylcholine receptor expression in human lung carcinoma cells through peroxisome proliferator-activated receptor gamma-independent signals.
Sun X; Ritzenthaler JD; Zheng Y; Roman J; Han S
Mol Cancer Ther; 2009 Jan; 8(1):110-8. PubMed ID: 19139119
[TBL] [Abstract][Full Text] [Related]
5. Dual inhibition of phosphatidylinositol 3-kinase/Akt and mammalian target of rapamycin signaling in human nonsmall cell lung cancer cells by a dietary flavonoid fisetin.
Khan N; Afaq F; Khusro FH; Mustafa Adhami V; Suh Y; Mukhtar H
Int J Cancer; 2012 Apr; 130(7):1695-705. PubMed ID: 21618507
[TBL] [Abstract][Full Text] [Related]
6. Pioglitazone, a PPARγ agonist, attenuates PDGF-induced vascular smooth muscle cell proliferation through AMPK-dependent and AMPK-independent inhibition of mTOR/p70S6K and ERK signaling.
Osman I; Segar L
Biochem Pharmacol; 2016 Feb; 101():54-70. PubMed ID: 26643070
[TBL] [Abstract][Full Text] [Related]
7. Activation of AMPK by Telmisartan Decreases Basal and PDGF-stimulated VSMC Proliferation via Inhibiting the mTOR/p70S6K Signaling Axis.
Hwang YJ; Park JH; Cho DH
J Korean Med Sci; 2020 Sep; 35(35):e289. PubMed ID: 32893519
[TBL] [Abstract][Full Text] [Related]
8. PPARgamma activator rosiglitazone inhibits cell migration via upregulation of PTEN in human hepatocarcinoma cell line BEL-7404.
Zhang W; Wu N; Li Z; Wang L; Jin J; Zha XL
Cancer Biol Ther; 2006 Aug; 5(8):1008-14. PubMed ID: 16775433
[TBL] [Abstract][Full Text] [Related]
9. The inhibition of insulin-stimulated proliferation of vascular smooth muscle cells by rosiglitazone is mediated by the Akt-mTOR-P70S6K pathway.
Park S; Lim S; Chang W; Song H; Lee S; Song BW; Kim HJ; Cha MJ; Choi E; Jang Y; Chung N; Cho SY; Hwang KC
Yonsei Med J; 2008 Aug; 49(4):592-600. PubMed ID: 18729301
[TBL] [Abstract][Full Text] [Related]
10. Bexarotene inhibits the viability of non-small cell lung cancer cells via slc10a2/PPARγ/PTEN/mTOR signaling pathway.
Ai X; Mao F; Shen S; Shentu Y; Wang J; Lu S
BMC Cancer; 2018 Apr; 18(1):407. PubMed ID: 29642873
[TBL] [Abstract][Full Text] [Related]
11. Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition.
Sun SY; Rosenberg LM; Wang X; Zhou Z; Yue P; Fu H; Khuri FR
Cancer Res; 2005 Aug; 65(16):7052-8. PubMed ID: 16103051
[TBL] [Abstract][Full Text] [Related]
12. Rosiglitazone inhibits insulin-like growth factor‑1-induced polycystic kidney disease cell growth and p70S6 kinase activation.
Liu C; Zhang Y; Yuan L; Fu L; Mei C
Mol Med Rep; 2013 Sep; 8(3):861-4. PubMed ID: 23864113
[TBL] [Abstract][Full Text] [Related]
13. Upregulation of PTEN involved in rosiglitazone-induced apoptosis in human hepatocellular carcinoma cells.
Cao LQ; Chen XL; Wang Q; Huang XH; Zhen MC; Zhang LJ; Li W; Bi J
Acta Pharmacol Sin; 2007 Jun; 28(6):879-87. PubMed ID: 17506947
[TBL] [Abstract][Full Text] [Related]
14. Troglitazone acutely inhibits protein synthesis in endothelial cells via a novel mechanism involving protein phosphatase 2A-dependent p70 S6 kinase inhibition.
Cho DH; Choi YJ; Jo SA; Ryou J; Kim JY; Chung J; Jo I
Am J Physiol Cell Physiol; 2006 Aug; 291(2):C317-26. PubMed ID: 16825603
[TBL] [Abstract][Full Text] [Related]
15. Epimagnolin targeting on an active pocket of mammalian target of rapamycin suppressed cell transformation and colony growth of lung cancer cells.
Yoo SM; Lee CJ; Kang HC; Lee HS; Lee JY; Kim KD; Kim DJ; An HJ; Cho YY
Mol Carcinog; 2019 Jul; 58(7):1221-1233. PubMed ID: 30887599
[TBL] [Abstract][Full Text] [Related]
16. Thiazolidinediones inhibit insulin-like growth factor-i-induced activation of p70S6 kinase and suppress insulin-like growth factor-I tumor-promoting activity.
He G; Sung YM; Digiovanni J; Fischer SM
Cancer Res; 2006 Feb; 66(3):1873-8. PubMed ID: 16452250
[TBL] [Abstract][Full Text] [Related]
17. Repression of phosphoinositide-dependent protein kinase 1 expression by ciglitazone via Egr-1 represents a new approach for inhibition of lung cancer cell growth.
Hann SS; Tang Q; Zheng F; Zhao S; Chen J; Wang Z
Mol Cancer; 2014 Jun; 13():149. PubMed ID: 24925061
[TBL] [Abstract][Full Text] [Related]
18. Repression of integrin-linked kinase by antidiabetes drugs through cross-talk of PPARγ- and AMPKα-dependent signaling: role of AP-2α and Sp1.
Hahn SS; Tang Q; Zheng F; Zhao S; Wu J; Chen J
Cell Signal; 2014 Mar; 26(3):639-47. PubMed ID: 24361375
[TBL] [Abstract][Full Text] [Related]
19. Luteoloside induces G
Zhou M; Shen S; Zhao X; Gong X
Biochem Biophys Res Commun; 2017 Dec; 494(1-2):263-269. PubMed ID: 29024631
[TBL] [Abstract][Full Text] [Related]
20. PPARgamma agonists sensitize PTEN-deficient resistant lung cancer cells to EGFR tyrosine kinase inhibitors by inducing autophagy.
To KKW; Wu WKK; Loong HHF
Eur J Pharmacol; 2018 Mar; 823():19-26. PubMed ID: 29378193
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
